Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin
暂无分享,去创建一个
Stefanie Hennig | Joakim Nyberg | Mats O Karlsson | Andrew C Hooker | J. Backman | S. Hennig | J. Nyberg | A. Hooker | K. Hoppu | Janne T Backman | Samuel Fanta | Kalle Hoppu | S. Fanta | M. Karlsson
[1] M O Karlsson,et al. Diagnosing Model Diagnostics , 2007, Clinical pharmacology and therapeutics.
[2] France Mentré,et al. Bayesian design criteria: Computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model , 1995, Journal of Pharmacokinetics and Biopharmaceutics.
[3] Andrew C. Hooker,et al. Simultaneous optimal experimental design on dose and sample times , 2009, Journal of Pharmacokinetics and Pharmacodynamics.
[4] M. Foracchia,et al. POPED, a software for optimal experiment design in population kinetics , 2004, Comput. Methods Programs Biomed..
[5] Marie Davidian,et al. Nonlinear Models for Repeated Measurement Data , 1995 .
[6] Mats O. Karlsson,et al. Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[7] C. Staatz,et al. Sampling Times for Monitoring Tacrolimus in Stable Adult Liver Transplant Recipients , 2004, Therapeutic drug monitoring.
[8] K. Hoppu,et al. Pharmacokinetically determined cyclosporine dosage in young children , 2004, Pediatric Nephrology.
[9] Barbara Bogacka,et al. Compound and other optimum designs for systems of nonlinear differential equations arising in chemical kinetics , 2002 .
[10] Andrew C. Hooker,et al. Robust Population Pharmacokinetic Experiment Design , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[11] Mats O. Karlsson,et al. Graphical Displays for Modeling Population Data , 2006 .
[12] S. Chandy,et al. A limited sampling strategy for tacrolimus in renal transplant patients. , 2008, British journal of clinical pharmacology.
[13] M O Karlsson,et al. Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates. , 2007, British journal of clinical pharmacology.
[14] Nicholas H. G. Holford,et al. A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.
[15] J. Ringers,et al. Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice , 2007, Alimentary pharmacology & therapeutics.
[16] Stephen B. Duffull,et al. Prospective Evaluation of a D-Optimal Designed Population Pharmacokinetic Study , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[17] France Mentré,et al. Optimal Sampling Times for Bayesian Estimation of the Pharmacokinetic Parameters of Nortriptyline During Therapeutic Drug Monitoring , 1999, Journal of Pharmacokinetics and Biopharmaceutics.
[18] Stefanie Hennig,et al. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. , 2007, British journal of clinical pharmacology.
[19] Barbara Bogacka,et al. Compound D - and D S -optimum designs for determining the order of a chemical reaction , 1997 .